CORPORATE DEVELOPMENT PROGRAM GRADUATES

Life Quality Technologies, LLC intends to use its proprietary cooling technology in the design, development, testing, and marketing of a family of discreet, lightweight, wearable electronic cooling devices. Its products will be targeted at persons with transient, brief body-heating episodes—in particular baby-boomer women suffering from menopausal hot flashes. Contact Denise Polacek at polacek@lqtechnologies.com.

OneWorld Biotech, Inc. offers flexible, integrated and custom molecular and cellular biology services and solutions (gene cloning and vector construction, protein expression and purification, DNA and RNA analysis, and cell line and assay development) on a fee-for-service outsourcing arrangement and advanced and comprehensive early stage R&D support through client-sponsored specialized projects, retained consultancy and strategic partnerships to US biotech and pharmaceutical companies and government laboratories. Contact Malla Padidam, Ph.D., President at support@oneworldbio.com.

Pepthera, LLC is an early stage biotechnology company developing peptide-based medicines to address the unmet medical needs of patients with leptin-responsive conditions associated with obesity. Contact: Laszlo Otvos, Ph.D. at otvos@temple.edu.

 CURRENT CORPORATE DEVELOPMENT PROGRAM COMPANIES

CD Diagnostics, LLC has developed a novel concept for testing an existing Total Joint Replacement for infection.  Contact Mike Behr, President at mjbehr2@comcast.netfor more information.

Technical Vision, Inc. is developing a unique vision device that will allow visually impaired and blind people to have dynamic perception of the space around them. Contact Sergey Naumovsky at sergey@technicalvisioninc.com.

Vascular Strategies, LLC is dedicated to the discovery and expansion of treatment options for Cardiovascular Disease. Our company is a complete resource for functional testing and development of therapeutic candidates for arresting and reversing atherosclerosis through modulation of High Density Lipoprotein (HDL), Reverse Cholesterol Transport (RCT), and Immune Mediators. Contact Steven J. Adelman, Ph.D., CEO at sadelman@vascularstrategy.com.

KIZ COMPANIES

AMT is a technology consulting company specializing in bioinformatics and computational biology software and services.  AMT’s computational software brings together a unique combination of enhanced import, analysis and visualization capabilities that are particularly useful for biologists and researchers who work with microarray and mass spectrometry data.  Contact Chris Chiu, Chief Research Scientist and Managing Director at chris.chiu@amtinfo.com

Biltmore Pharmaceutical Software Solutions has developed a hosted/outsourced business intelligence solution for the Sales and Marketing divisions of small to mid-tier pharmaceutical and biotech companies that addresses sales reporting, ad-hoc querying, dashboard/scorecarding, and incentive compensation needs.  Contact Mike Wexler at mwexler1110@comcast.net for more information.

BioLeap Inc. is a drug discovery company that applies its proprietary technology and drug design tools to therapeutically proven targets in order to significantly improve drug performance with novel compounds. BioLeap has internal pre-clinical development programs for anti-bacterials, hepatitis-C, and inflammation. Two of these programs involve established partnerships. Contact Gerry Evans, Executive Vice President, at ghe@bioleap.com.

Creative Footwear Technology, Inc. plans to design, manufacture and sell footwear using sound biomechanical principles.  The footwear will be comfortable, functional and therapeutic and will target people who have any of a variety of foot pathologies including but not limited to those with arthritic feet and diabetic patients at risk for foot ulceration.  Contact Richard Posoff at richardposoff@gmail.com. 

CureDM is a biopharmaceutical company working to produce new therapies that may prevent, ameliorate, or reverse diabetes mellitus. The company has discovered the novel Human proIslet Peptide (HIP) associated with insulin production in the pancreas. Compounds under development have the potential to restore, maintain, and protect the body’s ability to produce insulin, thereby reducing or eliminating the need for insulin injections. For more information, contact H.Joseph Reiser, Ph.D., CEO at HJReiser@curedm.com.

Drug Detection Solutions, LLC is a medical instrument manufacturer focused on devices to detect drugs of abuse and weapons of mass destruction. The company is currently working on a project with the State Department and the International Narcotics Agency to measure opium exposure in the families and children of workers in the opium poppy fields in Afghanistan to help reduce opium production in that country. David Martin will be conducting training in Dubai of Afghan doctors and law enforcement officials to use Drug Detection Solutions patented technologies. Contact David Martin at david.martin@jmj-technologies.com.

 
EyeIC Inc. is a medical device company using proprietary technology to create improved tools for the monitoring and management of glaucoma and retinal diseases. The company’s first product, Matched-Flicker, captures and processes retinal photographs to enable doctors to monitor change in condition. A pilot study is being conducted with a prototype. A follow-on device, RetinoCAD, will be an automated change indication product that will increase ease of use. Contact Ira Wallace at iwallace@eyeic.com.

Galleon Pharmaceuticals, Inc. is a discovery-stage company focused on building a portfolio of novel medicines for prevalent breathing-control conditions including sleep apnea, ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, and obesity-hypoventilation syndrome. The initial underlying technology was licensed from a major university and is underpinned by recent advances in the understanding of the biochemical and physiological basis by which the body regulates breathing. The therapeutic concept for one of the approaches is supported by a small clinical proof-of-concept trial.   Contact Jim Mannion at jimmannion@galleonpharma.com.

Immunome, Inc. is a biopharmaceutical company with a novel Native Human Antibody (N-huMAB) generation platform that, unlike most competitive methods, isolates human antibodies in their native configurations. An integrated R & D platform provides substantial cost-advantage in the development and production of the N-huMABs, combining high-throughput screening, function-driven discovery, and hybridoma scale-up for drug production. Immunome has demonstrated proof-of-concept in neurodegenerative disease and biodefense. Contact Scott Dessain at scott@immunomeinc.com.

Innovations Foresight, LLC is a discovery organization for synergistic vision technology solutions. The company’s EazyTrack software will track patient names, arteries, and veins and will automatically calculate the AV ratio for the individual patients. Contact Tom Cockley at tom@innovationsforesight.com.

Hy BioPharma is a pharmaceutical biotechnology company commercializing an advanced drug technology (HBP-347) focused on the treatment of cancer, autoimmune disorders, and inflammation. Clinical studies using HBP-347 in patients with glioma brain tumors, cutaneous T cell lymphoma, and psoriasis confirm the safety and efficacy of HBP-347 in these patients. Hy BioPharma’s vision is to bring this technology rapidly to market with new drug applications (NDAs) for two FDA-approved Orphan indications. Contact Alfonso Tobia at ajtobia@aol.com.

LIMR Chemical Genomics Center, Inc. provides state of the art, highly automated, research materials management to accelerate and support high throughput screening. Contact Mel Reichman at reichmanm@mlhs.org.

MBF Therapeutics (MBFT) is a development-stage veterinary oncology company dedicated to advancing the standard of care for companion animals by commercializing safe, effective and humane cancer treatments for the high value companion animal market.  Contact Tom Tillett, President & CEO at info@mbftherapeutics.com.

Midway Pharmaceuticals creates proprietary drugs for the treatment of bacteria-mediated GI diseases, such as febrile neutropenia, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), necrotizing enterocolitis (NEC), radiation-induced enteritis, and traveler’s diarrhea. The initial indication for Midway’s first drug, MDY-1001, is the prevention of febrile neutropenia in patients at risk due to treatment for acute leukemia and other cancers. In 2006, the company received a $500,000 investment from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania for proof of concept and safety studies of MDY-1001 to inhibit the pathogenic behavior of bacteria in the GI tract. Contact r.pamukcu@midwaypharma.com.

Mitergy, LLC is an early-stage, drug discovery company focused on the progressive cell death that accompanies several human diseases, including stroke; progressive heart failure; and neurodegenerative diseases such as Parkinson's, Alzheimer's and Amyotropic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Mitergy's preclinical research has characterized a superior disease-related drug target that is activated during the development of congestive heart failure associated with chemotherapy. Mitergy's cardio protective, small molecule drugs are also now being tested in animal models of neurodegeneration. Contact Paul Anziano at anziano@mitergybiotech.com.

NexusPharma, Inc. is dedicated to the discovery of novel non-cytotoxic anti-cancer agents based on small-molecule protein-protein interaction inhibitors (PPIIs). Applying its patented technologies discovered at Fox Chase Cancer Center , NexusPharma is developing a portfolio of small-molecule candidates that target selected cancer-promoting protein-protein interactions and inhibit critical cancer signaling networks. Contact Lutz Weber at Lutz.weber@nexuspharm.com.

NuPathe, Inc. is a specialty pharmaceutical company developing therapeutic products for neurological and psychiatric diseases by licensing or acquiring product opportunities that can have an immediate and significant impact on disease treatment and management. Primary areas of focus include migraine, Parkinson's disease, Restless Legs Syndrome (RLS), schizophrenia, and cognitive disorders. The company has completed Phase I clinical studies of NP101 Migraine SmartRelief™, a novel transdermal formulation of sumatriptan. Contact Ezra Felker, VP Business Development, at efelker@nupathe.com.

PerioNovum, Inc. is a development stage company developing nonsurgical products for treatment and prevention of periodontal disease and perio-implantitis.  For more information, contact Jeffrey D. Glen, DDS, President at Jdglen5224@aol.com.

Polyviron, LLC is developing diagnostics and treatments for polyoma viruses.  Contact Kamel Khalili at kkhalili@temple.edu.

Prescient Medical, Inc. is developing new diagnostic techniques and treatments for the prevention of heart attacks caused by a build-up of plaque. The company’s product development portfolio includes the vPredict™ Optical Catheter System to detect and characterize atherosclerotic plaques and the vProtect™ Luminal Shield to treat soft, atherosclerotic lesions that may be vulnerable to rupture. These devices will allow interventional cardiologists to more precisely tailor focal treatment according to the unique needs of each patient. Contact Scott Durbin, CFO, at sdurbin@prescientmedical.com.

Proplex Technologies, LLC is working to identify markers from which to develop diagnostic kits for detection of early-stage cancers. One of the products they are currently working on is a technology to identify the stages of breast cancer. Contact Frank Chang, Ph.D. at frank.chang@temple.edu.

Quiq, Inc. has developed a proprietary system that enables physicians to fill patient prescriptions directly at the point of care. The QuiqMedsTM system is installed at the physician’s office and provides services such as order entry and processing, patient database querying, inventory management, reordering/restocking, and administrative reporting functions. Contact Mel Stein at mstein@quiqmeds.com.

R&D Green Materials, LLC is a start-up company founded in 2004 to develop bio-based, biodegradable plastic products from plant materials.   Please contact Dr. Dara L. Woerdeman, President & CEO at woerdeman@randdgreenmaterials.com. 

Refocus Displays, Inc. has developed a computer eyestrain relieving device to address the problem of reduced productivity caused by near-point eyestrain.  The Refocus Display slowly and continuously moves the display screen toward and away from the user to change the focal distance.  For more information, contact Roger Birkbeck, President at info@refocusdisplays.com.

Solixia, Inc. is an early-stage life science company formed to develop better imaging and treatment options for aggressive cancer. Our product candidates are based on a proprietary innovation in radiochemistry called the HotDot™ radiolabel.  The HotDotTM radiolabel is designed to enable tumor-targeting molecules such as antibodies to deliver 10X the radioactivity to a tumor than is currently possible.  This will improve both imaging sensitivity and therapeutic efficacy.  Contact Irene Susantio, CEO at irene.susantio@solixia.com.  

Topaz Pharmaceuticals, Inc. is a pharmaceutical company dedicated exclusively to children’s health and well-being. The company is developing a novel and kid-friendly formulation of a naturally derived, quick acting ingredient that is lethal to head and body lice. Contact Nick Spring at nick_spring@topazpharma.com.

Vitae Pharmaceuticals is an emerging pharmaceutical company working to discover, develop and commercialize new compounds for therapeutic areas such as cardiovascular disease, diabetes, obesity, and Alzheimer's. The company’s discovery tool, CONTOURTM, has yielded candidates in multiple therapeutic areas. In 2005, Vitae formed a partnership with GlaxoSmithKline to develop a candidate for treating high blood pressure and in 2007 the company formed a strategic alliance with Boehringer Ingelheim to develop a target for treating diabetes and metabolic syndrome-related diseases. Vitae is expanding discovery efforts into virology, cancer, and metabolic disease. Contact Ken Jones, Controller, at kjones@vitaerx.com.

The mission of ZSX Medical, LLC is to design and develop surgical access and closure systems that improve surgical outcomes by reducing the iatrogenic damage of surgery, reducing operative time, reducing complications, and freeing surgeons to focus on the fundamental demands of the procedure.  For more information, contact Dan Mazzucco, Ph.D. at danm@fetamed.com.